HC Wainwright Reiterates "Buy" Rating for Beam Therapeutics (NASDAQ:BEAM)

HC Wainwright reiterated their buy rating on shares of Beam Therapeutics (NASDAQ:BEAM - Free Report) in a research report released on Monday,Benzinga reports. They currently have a $80.00 price target on the stock. HC Wainwright also issued estimates for Beam Therapeutics' Q1 2026 earnings at ($0.83) EPS, Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.81) EPS, FY2026 earnings at ($3.30) EPS, FY2027 earnings at ($3.00) EPS, FY2028 earnings at ($1.91) EPS and FY2029 earnings at ($1.44) EPS.

A number of other equities analysts also recently issued reports on the company. Wedbush reissued an "outperform" rating and set a $57.00 target price on shares of Beam Therapeutics in a research note on Monday, January 13th. Royal Bank of Canada reduced their price objective on Beam Therapeutics from $27.00 to $24.00 and set a "sector perform" rating for the company in a report on Wednesday, November 6th. Cantor Fitzgerald upgraded Beam Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Wednesday, January 29th. Leerink Partnrs upgraded Beam Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, November 6th. Finally, Scotiabank started coverage on shares of Beam Therapeutics in a research report on Wednesday, October 16th. They issued a "sector outperform" rating and a $24.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $47.67.

Beam Therapeutics Stock Performance

NASDAQ BEAM traded down $0.17 during trading on Monday, reaching $27.65. The company's stock had a trading volume of 1,496,937 shares, compared to its average volume of 1,145,218. The business's fifty day moving average price is $26.49 and its 200-day moving average price is $25.77. Beam Therapeutics has a twelve month low of $20.84 and a twelve month high of $49.50. The firm has a market cap of $2.29 billion, a price-to-earnings ratio of -15.71 and a beta of 1.92.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($1.17) earnings per share for the quarter, missing analysts' consensus estimates of ($1.16) by ($0.01). The company had revenue of $14.30 million for the quarter, compared to analyst estimates of $14.52 million. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The firm's revenue was down 16.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.22) earnings per share. As a group, sell-side analysts forecast that Beam Therapeutics will post -4.57 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Christine Bellon sold 1,241 shares of the company's stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $24.68, for a total value of $30,627.88. Following the completion of the sale, the insider now owns 102,968 shares of the company's stock, valued at $2,541,250.24. This represents a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO John M. Evans sold 30,000 shares of the business's stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $26.75, for a total value of $802,500.00. Following the transaction, the chief executive officer now directly owns 908,659 shares in the company, valued at $24,306,628.25. This trade represents a 3.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Beam Therapeutics

A number of institutional investors have recently added to or reduced their stakes in BEAM. Vestmark Advisory Solutions Inc. grew its stake in shares of Beam Therapeutics by 29.3% during the fourth quarter. Vestmark Advisory Solutions Inc. now owns 173,152 shares of the company's stock valued at $4,482,000 after acquiring an additional 39,250 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Beam Therapeutics in the fourth quarter worth $703,000. Proficio Capital Partners LLC acquired a new stake in Beam Therapeutics in the fourth quarter valued at $406,000. Atria Investments Inc boosted its stake in Beam Therapeutics by 17.1% during the 4th quarter. Atria Investments Inc now owns 9,562 shares of the company's stock valued at $237,000 after acquiring an additional 1,395 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Beam Therapeutics by 3.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 648,945 shares of the company's stock worth $16,094,000 after acquiring an additional 19,453 shares in the last quarter. Institutional investors and hedge funds own 99.68% of the company's stock.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.